Tech Company Financing Transactions
Latus Bio Funding Round
8VC, Ben Franklin Technology Partners and BioAdvance Ventures participated in a $43 million Series A capital raise for Latus Bio. The round closed on 5/5/2026.
Transaction Overview
Company Name
Announced On
5/5/2026
Transaction Type
Venture Equity
Amount
$43,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to expand operations, including initial clinical data from its two programs, which include LTS-201 for Huntington's disease and LTS-101 for late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Philadelphia, PA Undisclosed
USA
Philadelphia, PA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
Latus develops innovative gene therapy candidates that use precision delivery with the goal of improving the lives of patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Peter Ghoroghchian
Chief Scientific Officer
Jang-Ho Cha
VP - Bus. Development
John Connelly
VP - Operations
Kerry Eischen
Browse more venture capital transactions:
Prev: 5/5/2026: ZyG venture capital transaction
Next: 5/5/2026: Astrocade AI venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC transactions reported here come from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs